What Quiver Bioscience does

Quiver Bioscience is a Cambridge, MA-based biotechnology company (founded 2014, 101–250 employees) that operates an AI-driven drug discovery platform focused on central nervous system (CNS) diseases. The platform integrates patient-derived induced pluripotent stem cell (iPSC) neuronal models, proprietary all-optical electrophysiology instrumentation (Swarm, Firefly, and Mantis), and AI/ML workflows orchestrated through its QnAi agent. The company's Brain GPS perturbation atlas is built on approximately 18,000 gene perturbations, 3,500 drug fingerprints, and over 1.5 billion action potentials recorded across more than 30 million neurons, enabling target identification, mechanism-of-action profiling, and IND-enabling candidate selection across chronic pain, developmental and epileptic encephalopathies, and neurodevelopmental disorders.

The wholly owned pipeline includes QV-2421 (a Nav1.7 antisense oligonucleotide for chronic pain), a UBE3A ASO for Dup15q syndrome, Nav1.8 ASO, a dual Nav1.7/1.8 ASO, programs in STXBP1, SYNGAP1, FMR1, and SCN8A encephalopathies, and a TSC2 small molecule. Quiver's commercial model is a hybrid of platform-as-a-service and risk-sharing collaborations: it generates revenue from research-funded discovery partnerships (e.g., Angelini Pharma with up to $120M in potential milestones, QurAlis for ALS/FTD, and additional undisclosed pharma partners signed in Q4 2025), supplemented by non-dilutive grant funding (notably a $9.3M NIH HEAL Initiative award in May 2026) and patient-advocacy-backed programs. The 2018 acquisition of Pairnomix brought in epilepsy-focused assets and the STXBP1, SYNGAP1, and SCN8A programs, while the company's recent CEO transition (Graham Dempsey, June 2025) signals a shift from platform development toward clinical-stage execution and broader pharma partnership expansion.

Name

Quiver Bioscience

Legal name

Quiver Bioscience Inc.

Website

https://quiverbioscience.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

101–250 employees

Short description

Quiver Bioscience is an AI-native CNS drug discovery company using patient-derived iPSC neurons, all-optical electrophysiology, and proprietary AI/ML to identify and advance antisense oligonucleotide and small-molecule therapeutics for chronic pain, epilepsy, and neurodevelopmental disorders.

Ownership category

akta.pro rank

Product category

CNS Drug Discovery & Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Analytical Laboratory Instrument Manufacturing (334516)

SIC

Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industries

Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling) (HLAAAIAF), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• CNS drug discovery
• IPSC neuronal models
• All-optical electrophysiology
• AI-driven therapeutics
• Antisense oligonucleotide therapeutics

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Strategic research collaborations and licensing agreements: Multi-year collaboration and licensing deals with pharmaceutical partners. Quiver receives an undisclosed advance payment, support for defined research activities, additional licensing fees, plus milestone payments of up to $120 million and royalties upon partner election of identified drug targets. Example: Angelini Pharma collaboration for DEEs (announced Feb 2026).
2. Research collaboration partnerships: Targeted research collaborations with biotech/pharma partners covering shared development of platform-derived therapeutic candidates, such as the QurAlis Fragile X Syndrome collaboration (announced May 2025).
3. Non-dilutive grant funding: Government grant funding from NIH and related agencies. Examples include the NIH HEAL Initiative UG3/UH3 cooperative agreement (UG3NS146009) providing up to $9.3 million in direct funding and approximately $20 million in total potential development support for QV-2421. CEO Graham Dempsey has led more than $30M in non-dilutive grant funding from NIH SBIR Programs and CNS Foundations since the company's inception.
4. Strategic mission-driven investments from family offices: Targeted mission-driven strategic investments from family offices (e.g., the Porta family of Argentina) to advance specific wholly-owned programs such as the UBE3A ASO program for Dup15q syndrome.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Quiver Bioscience operates an integrated CNS drug discovery platform that combines patient-derived iPSC neuronal models, proprietary all-optical electrophysiology instruments (Swarm, Firefly, Mantis), and AI/ML analytics (QnAi, Brain GPS perturbation atlas) to identify, validate, and advance therapeutic targets and candidate molecules. On top of the platform, the company runs a wholly-owned therapeutic pipeline of antisense oligonucleotide (ASO) and small molecule drug candidates focused on chronic pain, genetic epilepsies, neurodevelopmental disorders, and rare CNS diseases.

Product overview

Quiver Bioscience offers a single integrated CNS drug discovery and development offering organized as a platform-plus-modules architecture, anchored by the Quiver Discovery Platform with three named modules — Models (patient-derived iPSC neuronal models), Signals (all-optical electrophysiology assays and Swarm/Firefly/Mantis instruments), and Insights (AI models, the perturbation atlas, and the QnAi question-and-answer AI agent) — collectively branded in publications as the Genomic Positioning System (Brain GPS). On top of this platform, Quiver advances a wholly owned therapeutic pipeline of antisense oligonucleotide and small molecule candidates, including lead program QV-2421 (Nav1.7 ASO for chronic neuropathic pain), the UBE3A ASO for Dup15q syndrome, plus wholly owned programs in Nav1.8, STXBP1, SYNGAP1, FMR1, SCN8A, dual Nav1.7/1.8, and TSC2 small molecule, and also runs partnered discovery programs (e.g., with Angelini Pharma, QurAlis, and Vertex/UCB/NIH/Amgen/Takeda/GSK/Merck).

Differentiator

Problem solved

Functional benefit

Brands

• Quiver Discovery Platform: Proprietary integrated drug discovery platform combining all-optical electrophysiology, patient-derived iPSC neuronal models, single-cell transcriptomics, and AI/ML analytics.
• QnAi (Quiver's Question and Answer AI)
• Brain GPS (Genomic Positioning System)

Products and services

• Quiver Discovery Platform Integrated three-pillar CNS drug discovery platform combining patient-derived iPSC neuronal models (Models), all-optical electrophysiology measurements (Signals), and AI/ML analytics (Insights) used to identify, validate, and prioritize therapeutic targets and candidate molecules for pharmaceutical and biotechnology partners. Anchored by 1.5B+ action potentials across 30M+ individual neurons, 18,000 gene perturbations, and 3,500 drug fingerprints.
• QV-2421 (Nav1.7 ASO) Wholly-owned antisense oligonucleotide candidate targeting the Nav1.7 voltage-gated sodium channel for chronic neuropathic pain, advancing through IND-enabling studies and first-in-human clinical trials with support from the NIH HEAL Initiative and Co-PI Dr. Charles Berde at Boston Children's Hospital.
• UBE3A ASO Program (Dup15q syndrome) Wholly-owned antisense oligonucleotide program for chromosome 15q duplication (Dup15q) syndrome designed to reduce excess UBE3A gene expression, with development candidate selection targeted for 2H 2026. Supported by the Dup15q Alliance collaboration and a strategic investment from the Porta family.
• Wholly-owned CNS ASO and small molecule pipeline (Nav1.8, STXBP1, SYNGAP1, FMR1, SCN8A, dual Nav1.7/1.8, TSC2) Additional wholly-owned therapeutic programs identified by the Quiver platform: Nav1.8 ASO (chronic pain), STXBP1 and SYNGAP1 ASOs (developmental and epileptic encephalopathies), FMR1 (Fragile X Syndrome), SCN8A ASO, dual Nav1.7/1.8 ASO, and TSC2 small molecule (Tuberous Sclerosis).
• Angelini Pharma DEE Collaboration and Licensing Agreement Multi-year research collaboration and licensing agreement with Angelini Pharma to discover and advance novel therapeutics for Developmental and Epileptic Encephalopathies (DEEs); Quiver is eligible for up to $120 million in milestone payments plus royalties and Angelini secures exclusive global license rights to collaboration-generated drug targets.
• QurAlis Fragile X Syndrome Research Collaboration Research collaboration with QurAlis to advance a novel therapeutic approach for Fragile X Syndrome using Quiver's discovery platform; QurAlis logo also appears on Quiver's pipeline page for the FMR1 program.

Quantifiable outcome

• 1.5B+ action potentials and 30M+ individual neurons analyzed across 18,000 gene perturbations and 3,500 drug fingerprints; signals page cites 126,132,905+ neurons and 9.6B+ action potentials to date
• +3 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability14 records

Feature6 records

Partnerships

Six partnerships are on record, tiered core, flagship and minor.

• National Institutes of Health (NIH) — National Institute of Neurological Disorders and Stroke (NINDS), HEAL InitiativecoreOthers · 4 May 2026Phased UG3/UH3 cooperative agreement (award number UG3NS146009) under NIH's Helping to End Addiction Long-term (HEAL) Initiative, providing up to $9.3 million in direct funding and access to NIH-supported CMC and IND-enabling development resources representing total potential development support of approximately $20 million. Funds advancement of QV-2421 (Nav1.7 ASO) for chronic neuropathic pain through preclinical studies and a first-in-human Phase Ib trial in erythromelalgia patients.
• Boston Children's Hospital (Dr. Charles Berde, MD, PhD)coreStrategic or Co-development Partner · 4 May 2026Established collaboration with Dr. Charles Berde (Sara Page Mayo Chair in Pediatric Pain Medicine; Professor of Anesthesia at Harvard Medical School) as Co-Principal Investigator of the NIH HEAL Initiative award. Dr. Berde will conduct the Phase Ib trial of QV-2421 in patients affected by erythromelalgia. He also serves as a Senior Associate on Quiver's Scientific Advisory Board.
• Angelini PharmaflagshipStrategic or Co-development Partner · 23 February 2026Multi-year collaboration and licensing agreement to discover and advance novel therapeutics for Developmental and Epileptic Encephalopathies (DEEs), a group of rare genetic diseases causing severe treatment-resistant seizures in children. Quiver will leverage its AI-powered drug discovery platform combining human neuronal models, single-cell transcriptomics, and optical electrophysiology; Angelini Pharma will provide its brain health and epilepsy drug development expertise. Quiver receives an undisclosed advance payment plus support for defined research activities and additional licensing fees; Quiver is also eligible to receive additional milestone payments of up to $120 million and royalties upon Angelini's election of identified drug targets. Angelini secures exclusive global license rights to collaboration-generated drug targets.
• Destum PartnersminorOthers · 23 February 2026Acted as transaction advisor to Quiver Bioscience on the Angelini Pharma collaboration and licensing agreement.
• QurAliscoreStrategic or Co-development Partner · 15 May 2025Research collaboration to advance a novel therapeutic approach for Fragile X Syndrome using Quiver's discovery platform. QurAlis is also referenced on Quiver's pipeline table for the FMR1 (Fragile X Syndrome) program and is shown as a pipeline partner logo on the website, indicating an integrated co-development relationship combining QurAlis' therapeutic expertise with Quiver's platform capabilities.
• Dup15q AlliancecoreGTM or Marketing Partner · 19 March 2025Collaboration to advance Quiver's antisense oligonucleotide therapeutic program for Dup15q syndrome (UBE3A ASO). The Dup15q Alliance is a nonprofit that supports scientific and clinical research toward effective therapeutics and connects Quiver to affected families and clinical sites. The Alliance welcomed the April 2026 strategic investment from the Porta family as 'powerful signal of what's possible when families, science, and community come together around a shared goal.'

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Verge Genomics: AI-driven drug discovery company focused on neurodegenerative and CNS diseases, using human tissue-based disease models and machine learning to identify therapeutic targets. Directly comparable to Quiver in its application of AI/ML on human CNS biology for target identification and partner-led drug development.

Broad incumbents

• Recursion Pharmaceuticals: Publicly traded AI drug discovery company combining high-throughput biology, chemistry, and machine learning across multiple therapeutic areas. While broader in scope than Quiver, Recursion's platform approach of integrating proprietary wetware, automated experimentation, and AI maps directly to Quiver's lab-in-the-loop architecture and is a clear scale competitor in the AI-discovery space.
• Insitro: Machine-learning-driven drug discovery company combining induced pluripotent stem cell (iPSC) biology, CRISPR genomics, and AI/ML to predict drug behavior. Closely comparable to Quiver in its reliance on iPSC-derived human cell models and AI/ML for CNS and metabolic disease target identification.
• Schrödinger: Publicly traded computational chemistry and molecular simulation company partnering with pharma on AI-enabled drug design. Comparable to Quiver as a software- and physics-driven platform that licenses tools and co-discovers candidates, though focused on small-molecule design rather than functional CNS biology.
• Karuna Therapeutics: CNS-focused biotech developing therapies for schizophrenia and other neuropsychiatric conditions; acquired by Bristol Myers Squibb in 2024. Comparable as a CNS-focused partnership/acquisition target and indicator of pharma demand for CNS pipeline assets in the same therapeutic space Quiver is pursuing.
• Alnylam Pharmaceuticals: Commercial-stage leader in RNA interference (RNAi) therapeutics with CNS pipeline expansion. Comparable as an oligonucleotide modality leader whose CNS pipeline validates the broader ASO/siRNA approach that Quiver's wholly-owned ASO programs (Nav1.7, Nav1.8, STXBP1, SYNGAP1, UBE3A) are pursuing.

Emerging players

• Neumora Therapeutics: Clinical-stage CNS-focused biotech developing precision medicines for neuroscience indications including depression, Alzheimer's agitation, and Parkinson's. Comparable to Quiver in CNS focus and B2B/partnership-oriented business model, though at a more advanced clinical stage.
• QurAlis: CNS-focused clinical-stage biotech developing precision medicines for ALS and Fragile X Syndrome. Directly comparable as an active collaboration partner of Quiver on the Fragile X Syndrome program, operating in the same CNS precision-medicine space with overlapping scientific leadership (Jonathan Fleming, former Q-State CEO, serves on both boards).
• Cognito Therapeutics: Clinical-stage neuroscience company developing disease-modifying therapeutics for Alzheimer's disease using gamma-frequency neuromodulation. Comparable as a platform-driven CNS therapeutics company with multiple pharma partnerships and academic medical center collaborations in neurological indications.
• Beacon Biosignals: AI/ML analytics company that applies machine learning to EEG and other electrophysiology datasets to characterize CNS drug activity. Comparable to Quiver in applying computational analysis to large-scale neuronal electrophysiology data for CNS drug development, though focused on EEG rather than optical electrophysiology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/quiverbio
• LinkedInlinkedin.com/company/quiverbioscience

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles19 records

Funding overview

Funding rounds6 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Quiver Bioscience